Security profile of direct anticoagulants. Preferred use in atrial fibrillation

Clin Investig Arterioscler. 2019 Nov-Dec;31(6):263-270. doi: 10.1016/j.arteri.2019.03.002. Epub 2019 Jun 15.
[Article in English, Spanish]

Abstract

A multidisciplinary panel of cardiologists, neurologists, internal medicine and specialists in hemostasis and thrombosis has elaborated this document showing recent scientific evidences supporting a better profile of direct oral anticoagulants (DOACs) versus vitaminK antagonists (VKA), as well as the indications of specific antidotes and hemostatic agents to reverse the anticoagulant effects of DOACs. The analysis reinforces the best profile of DOACs and its special benefit in patients with basal high hemorrhagic risk.

Keywords: Anticoagulantes orales de acción directa; Antidotes; Antídotos; Direct oral anticoagulants; Gastrointestinal bleeding; Hemorragia gastrointestinal; Hemorragia intracraneal; Intracranial hemorrhage.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use
  • Antidotes / therapeutic use
  • Antithrombins / adverse effects*
  • Antithrombins / therapeutic use
  • Atrial Fibrillation / complications*
  • Cerebral Hemorrhage / chemically induced
  • Cerebral Hemorrhage / prevention & control
  • Cerebral Hemorrhage / therapy
  • Dabigatran / adverse effects
  • Dabigatran / therapeutic use
  • Gastrointestinal Hemorrhage / chemically induced
  • Gastrointestinal Hemorrhage / therapy
  • Hemorrhage / chemically induced
  • Hemorrhage / etiology
  • Hemorrhage / prevention & control*
  • Hemorrhage / therapy
  • Humans
  • Practice Guidelines as Topic
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Pyridones / adverse effects
  • Pyridones / therapeutic use
  • Risk Factors
  • Rivaroxaban / adverse effects
  • Rivaroxaban / therapeutic use
  • Stroke / etiology
  • Stroke / prevention & control*
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antidotes
  • Antithrombins
  • Pyrazoles
  • Pyridines
  • Pyridones
  • Thiazoles
  • apixaban
  • idarucizumab
  • Rivaroxaban
  • Dabigatran
  • edoxaban